BioWa Announces Extended Licensing to MedImmune of BioWa's POTELLIGENT® Technology
News Oct 25, 2007
BioWa, Inc. has announced that it has entered into a second agreement with MedImmune to provide additional access to BioWa's patented POTELLIGENT® Technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies.
The agreement grants to MedImmune non-exclusive license rights to develop, manufacture and market antibodies based on POTELLIGENT® Technology for an undisclosed number of targets. In return, BioWa receives from MedImmune certain fees and milestone payments during product development, as well as royalties on marketed products using ADCC enhanced antibodies.
"We are pleased to extend our relationship with MedImmune, a world-leading biologics business and the cornerstone to AstraZeneca's plans to establish a major international presence in the research and development of biological therapeutics," said Dr. Masamichi Koike, President and CEO of BioWa. "With MedImmune's superior expertise in antibody-based drug development, this collaboration complements BioWa's mission to bring about the benefit of POTELLIGENT® Technology to patients as quickly as possible."
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE